ethosuximide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1087 77-67-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ethosuximide
  • ethosuxide
  • etosuximid
  • 3-Methyl-3-ethylsuccinimide
An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
  • Molecular weight: 141.17
  • Formula: C7H11NO2
  • CLOGP: 0.39
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 46.17
  • ALOGS: -0.15
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.25 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 39.20 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 25 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 118.30 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 93 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Nov. 2, 1960 FDA PARKE DAVIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Aplastic anaemia 115.66 42.70 28 1073 7125 46677836
Seizure 105.02 42.70 53 1048 123001 46561960
Multiple-drug resistance 84.73 42.70 18 1083 2547 46682414
Petit mal epilepsy 75.20 42.70 17 1084 3203 46681758
Intellectual disability 74.13 42.70 13 1088 669 46684292
Generalised tonic-clonic seizure 60.26 42.70 23 1078 27099 46657862
Suicidal behaviour 57.55 42.70 13 1088 2435 46682526
Drug ineffective 56.96 42.70 74 1027 677764 46007197
Epilepsy 55.87 42.70 21 1080 23717 46661244

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Seizure 93.79 47.85 47 729 98428 29853274
Petit mal epilepsy 71.57 47.85 16 760 2615 29949087
Benzodiazepine drug level decreased 54.42 47.85 7 769 35 29951667
Hepatic adenoma 54.25 47.85 7 769 36 29951666
Drug ineffective 48.50 47.85 51 725 340336 29611366

Pharmacologic Action:

SourceCodeDescription
ATC N03AD01 NERVOUS SYSTEM
ANTIEPILEPTICS
ANTIEPILEPTICS
Succinimide derivatives
ATC N03AD51 NERVOUS SYSTEM
ANTIEPILEPTICS
ANTIEPILEPTICS
Succinimide derivatives
FDA PE N0000008486 Decreased Central Nervous System Disorganized Electrical Activity
FDA EPC N0000175753 Anti-epileptic Agent
CHEBI has role CHEBI:35623 antiepileptic
CHEBI has role CHEBI:38215 calcium channel blockers
MeSH PA D000927 Anticonvulsants
MeSH PA D002491 Central Nervous System Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Absence seizure indication 79631006
Suicidal thoughts contraindication 6471006
Mood swings contraindication 18963009
Depressive disorder contraindication 35489007
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Kidney disease contraindication 90708001 DOID:557
Disease of blood AND/OR blood-forming organ contraindication 191124002 DOID:74
Acute intermittent porphyria contraindication 234422006 DOID:3890
Disease of liver contraindication 235856003 DOID:409
Neutropenic disorder contraindication 303011007 DOID:1227

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.31 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Voltage-dependent T-type calcium channel subunit alpha-1G Ion channel BLOCKER WOMBAT-PK CHEMBL

External reference:

IDSource
4018631 VUID
N0000146944 NUI
D00539 KEGG_DRUG
4018631 VANDF
C0015043 UMLSCUI
CHEBI:4887 CHEBI
3291 PUBCHEM_CID
CHEMBL696 ChEMBL_ID
DB00593 DRUGBANK_ID
D005013 MESH_DESCRIPTOR_UI
7182 IUPHAR_LIGAND_ID
1077 INN_ID
5SEH9X1D1D UNII
4135 RXNORM
4199 MMSL
4701 MMSL
d00227 MMSL
001631 NDDF
387244008 SNOMEDCT_US
44790008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Zarontin HUMAN PRESCRIPTION DRUG LABEL 1 0071-0237 CAPSULE 250 mg ORAL NDA 19 sections
Zarontin HUMAN PRESCRIPTION DRUG LABEL 1 0071-2418 SOLUTION 250 mg ORAL ANDA 19 sections
ETHOSUXIMIDE HUMAN PRESCRIPTION DRUG LABEL 1 0121-0670 SOLUTION 250 mg ORAL ANDA 18 sections
ETHOSUXIMIDE HUMAN PRESCRIPTION DRUG LABEL 1 23155-532 CAPSULE 250 mg ORAL ANDA 17 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 42806-711 CAPSULE 250 mg ORAL ANDA 18 sections
ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 46672-641 SOLUTION 250 mg ORAL ANDA 17 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 59762-2250 CAPSULE 250 mg ORAL NDA AUTHORIZED GENERIC 19 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 59762-2350 SOLUTION 250 mg ORAL ANDA 19 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 61748-024 SOLUTION 250 mg ORAL ANDA 17 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 61748-025 CAPSULE 250 mg ORAL ANDA 19 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 63629-8005 CAPSULE, LIQUID FILLED 250 mg ORAL ANDA 18 sections
ETHOSUXIMIDE HUMAN PRESCRIPTION DRUG LABEL 1 64380-878 CAPSULE 250 mg ORAL ANDA 12 sections
ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 68382-443 CAPSULE 250 1 ORAL ANDA 17 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 69387-108 CAPSULE, LIQUID FILLED 250 mg ORAL ANDA 19 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 69452-152 CAPSULE, LIQUID FILLED 250 mg ORAL ANDA 19 sections
ETHOSUXIMIDE HUMAN PRESCRIPTION DRUG LABEL 1 71335-1763 CAPSULE 250 mg ORAL ANDA 12 sections